Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Nanoparticle-Mediated Diagnosis and Treatment of Human Disease
share announcement

Nanoparticle-Mediated Diagnosis and Treatment of Human Disease

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 12952

Special Issue Editor

Dr. Teodora Mocan

E-Mail Website
Guest Editor
Physiology Department, Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania
Interests: nanomedicine; nanotoxicology; nanomediated immunoprophylaxis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanotechnology has opened up unique opportunities for diagnosis and treatment options due to particularities such as size, functionalization potential, as well as multimodal and synchronous mechanisms of action on living cells. This Special Edition is aiming to gather novel insights into the most recent directions toward nanotechnology-mediated diagnosis and treatment of human disease. Studies on nanopharmaceutic solutions designed for widely studied pathologies such as cancer, antimicrobial applications, and osteoregenerative applications are welcomed, together with more recent orientations, such as hematology, tissue regeneration, etc. Photothermal, nanotargeting, direct toxicity or other mechanistic approaches will equally find a place in this issue, with a special place given to theranostic applications. Evaluations of pharmacological  biodistribution and bioavailability, pharmacokinetics, and toxicity for newly designed nanostructures, as part of human disease prevention and diagnosis are also welcomed. High-quality theoretical reviews opening the path to novel pharmaceutical applications of nanoparticles in the diagnosis and treatment of human disorders will also be an integral part of this issue.

Dr. Teodora Mocan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • nanotechnology
  • diagnosis
  • treatment
  • human disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 3266 KiB  
Article
Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer
by Wei Zhou, Jiandong Huang, Qingwei Xiao, Shunmin Hu, Shijia Li, Jie Zheng, Zhiyun Du, Jiangling Peng and Huixiong Chen
Pharmaceutics 2022, 14(10), 2051; https://doi.org/10.3390/pharmaceutics14102051 - 26 Sep 2022
Cited by 4 | Viewed by 2849
Abstract
The prostate specific membrane antigen (PSMA), extensively overexpressed on prostate cancer (PCa) cell surface, has been validated as a diagnostic biomarker for PCa. However, insufficient attention has been paid to the development of PSMA-specific probes loaded with small chemical molecules for the in [...] Read more.
The prostate specific membrane antigen (PSMA), extensively overexpressed on prostate cancer (PCa) cell surface, has been validated as a diagnostic biomarker for PCa. However, insufficient attention has been paid to the development of PSMA-specific probes loaded with small chemical molecules for the in vivo molecular imaging of PCa. In this study, we innovatively labelled superparamagnetic iron oxide nanoparticles with a PSMA-targeting Glu-Urea-Lys scaffold. An optimized synthetic route was developed to offer a physiochemically stable probe. The probe demonstrated high binding affinity (0.38 ± 0.08 μg(Fe)/mL) and binding specificity to PSMA expressed on prostate cancer cell surface in vitro. In a xenograft PCa mouse model, significant negative contrast of the implanted prostate cancer xenograft could be specifically observed by MRI 6 h after tail vein injection of the tracer (Fe, 20 mg/kg), exhibiting its potential to exclusively enhance magnetic resonance detection of PCa. Full article
(This article belongs to the Special Issue Nanoparticle-Mediated Diagnosis and Treatment of Human Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 2082 KiB  
Review
Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles
by Romelia Pop, Alexandru-Flaviu Tăbăran, Andrei Paul Ungur, Andrada Negoescu and Cornel Cătoi
Pharmaceutics 2022, 14(7), 1463; https://doi.org/10.3390/pharmaceutics14071463 - 14 Jul 2022
Cited by 23 | Viewed by 9498
Abstract
Helicobacter pylori is the first formally recognized bacterial carcinogen and the most important single digestive pathogen responsible for the induction of gastroduodenal diseases such as gastritis, peptic ulcer, and, finally, gastric neoplasia. The recently reported high rates of antimicrobial drug resistance hamper the [...] Read more.
Helicobacter pylori is the first formally recognized bacterial carcinogen and the most important single digestive pathogen responsible for the induction of gastroduodenal diseases such as gastritis, peptic ulcer, and, finally, gastric neoplasia. The recently reported high rates of antimicrobial drug resistance hamper the current therapies of H. pylori, with therapeutic failure reaching up to 40% of patients. In this context, new treatment options and strategies are urgently needed, but the successful development of these new therapeutic tools is conditioned by the understanding of the high adaptability of H. pylori to the gastric acidic environment and the complex pathogenic mechanism. Due to several advantages, including good antibacterial efficiency, possible targeted delivery, and long tissular persistence, silver nanoparticles (AgNPs) offer the opportunity of exploring new strategies to improve the H. pylori therapy. A new paradigm in the therapy of H. pylori gastric infections using AgNPs has the potential to overcome the current medical limitations imposed by the H. pylori drug resistance, which is reported for most of the current organic antibiotics employed in the classical therapies. This manuscript provides an extensive overview of the pathology of H. pylori-induced gastritis, gastric cancer, and extradigestive diseases and highlights the possible benefits and limitations of employing AgNPs in the therapeutic strategies against H. pylori infections. Full article
(This article belongs to the Special Issue Nanoparticle-Mediated Diagnosis and Treatment of Human Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop